IL312361A - Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses - Google Patents

Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses

Info

Publication number
IL312361A
IL312361A IL312361A IL31236124A IL312361A IL 312361 A IL312361 A IL 312361A IL 312361 A IL312361 A IL 312361A IL 31236124 A IL31236124 A IL 31236124A IL 312361 A IL312361 A IL 312361A
Authority
IL
Israel
Prior art keywords
therapeutic uses
hematopoietic progenitor
progenitor kinase
degraders
bifunctional
Prior art date
Application number
IL312361A
Other languages
English (en)
Hebrew (he)
Inventor
John Buell
Frederick Cohen
Ryan Pemberton
Hunter P Shunatona
Lan Wang
Mark Edward Zak
Original Assignee
Gilead Sciences Inc
Nurix Therapeutics Inc
John Buell
Frederick Cohen
Ryan Pemberton
Hunter P Shunatona
Lan Wang
Mark Edward Zak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Nurix Therapeutics Inc, John Buell, Frederick Cohen, Ryan Pemberton, Hunter P Shunatona, Lan Wang, Mark Edward Zak filed Critical Gilead Sciences Inc
Publication of IL312361A publication Critical patent/IL312361A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
IL312361A 2021-11-10 2022-11-09 Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses IL312361A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
IL312361A true IL312361A (en) 2024-06-01

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312361A IL312361A (en) 2021-11-10 2022-11-09 Bifunctional joints of hematopoietic progenitor kinase and its therapeutic uses

Country Status (12)

Country Link
US (2) US12091426B2 (cg-RX-API-DMAC7.html)
EP (1) EP4430052A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543377A (cg-RX-API-DMAC7.html)
KR (1) KR20240101654A (cg-RX-API-DMAC7.html)
CN (1) CN118510786A (cg-RX-API-DMAC7.html)
AR (1) AR127625A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022388571A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235913A1 (cg-RX-API-DMAC7.html)
IL (1) IL312361A (cg-RX-API-DMAC7.html)
MX (1) MX2024005431A (cg-RX-API-DMAC7.html)
TW (1) TW202334170A (cg-RX-API-DMAC7.html)
WO (1) WO2023086399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
EP3873608A1 (en) * 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) * 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN114423463B (zh) * 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP7815127B2 (ja) 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
TWI918648B (zh) * 2020-05-06 2026-03-21 美商新銳思生物製藥股份有限公司 造血前驅細胞激酶之雙官能降解劑及其治療用途

Also Published As

Publication number Publication date
US20240018162A1 (en) 2024-01-18
WO2023086399A1 (en) 2023-05-19
US20240400587A1 (en) 2024-12-05
KR20240101654A (ko) 2024-07-02
MX2024005431A (es) 2024-07-19
JP2024543377A (ja) 2024-11-21
CA3235913A1 (en) 2023-05-19
EP4430052A1 (en) 2024-09-18
AU2022388571A1 (en) 2024-05-09
AR127625A1 (es) 2024-02-14
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
CN118510786A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
SI4367118T1 (sl) Bifunkcionalna sredstva za razgradnjo kinaz, povezanih z receptorjem za interlevkin-1, in terapevtske uporabe le-teh
IL285285A (en) Pairs of il-2 and their uses
IL287192A (en) Oligomeric polypeptides modulate t cells and methods for their use
IL292810A (en) Therapeutic compounds and methods of use
SG11202005147WA (en) Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
IL290513A (en) Formulations of benzazepine conjugates and their use
ZA202001442B (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
PL3983064T3 (pl) Modulatory cot i sposoby ich zastosowania
GB202108572D0 (en) Therapeutic compounds and their use
IL310096A (en) CD38 modulators and methods of using them
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
ZA202207188B (en) Liquid tasimelteon formulations and methods of use thereof
GB202019475D0 (en) Therapeutic compounds and their use
IL291543A (en) Medical preparations and their use
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
PL3897188T3 (pl) Algowy składnik pasz do kontroli skutków kokcydiozy i nekrotycznego zapalenia jelit u drobiu
IL290427A (en) Objects and methods for administering medical agents
GB201909573D0 (en) Modulation of T cell cytotoxicity and related therapy
PL3664770T3 (pl) Kosmetyk nasycony gazem terapeutycznym i sposoby nasycania
IL316562A (en) High-dose and convenient formulations of endoxifen
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
HK40116638A (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
IL311999A (en) New modulators of EHMT1 and EHMT2 and their therapeutic use
HK40089173A (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
IL263976B1 (en) Preparations containing memantin and melatonin